Russell Hales, M.D., is an assistant professor of radiation oncology and molecular radiation sciences at the Johns Hopkins University School of Medicine. He also is director of the thoracic multidisciplinary clinic. His research focuses on reconstructing health delivery models to enhance value and improve clinical outcomes. He also studies the effect of immunotherapy and RT in thoracic tumors. Dr. Hales was awarded an R21 grant to study the use of dynamic MRI in predicting tumor motion in patient with lung cancer. Taken together, his research focuses on optimizing patient outcomes using resources from physics, engineering, biology and health delivery systems. Dr. Hales’ efforts extend beyond radiation oncology and clinical management. He has helped to lead in the thoracic oncology program, which includes 20 faculty members and nearly 50 staff, to help chart a vision for this program’s future. In the last four years, the program has gradually transitioned from The Johns Hopkins Hospital campus to Johns Hopkins Bayview Medical Center. Dr. Hales was tasked to head the building and design committee that worked with architects to create a structure conducive to 21st century oncology care. His work extends beyond the bricks and mortar of the new cancer center today to team development within the thoracic oncology program. Simply put, the thoracic oncology move was designed to conceptualize the transition of care from department-based to disease-based medicine. As such, Dr. Hales has worked to integrate the efforts of specialists in medical oncology, thoracic surgery, interventional pulmonology, pathology and radiology. These experts share a clinical space focused on thoracic malignancies and bring a patient-centered model of care to their group. Dr. Hales graduated from Brigham Young University Summa Cum Laude and Valedictorian in 2001. He attended Johns Hopkins Medicine and graduated with an M.D. in 2005. He trained on the Osler Medical Service and attended residency at Johns Hopkins. He joined the faculty at Hopkins in 2010. Dr. Hales focus in program building, research and clinical endeavors is robust, but he understands the key role of academia in training future leaders in medicine. He has been awarded Teacher of the Year in the department of radiation oncology at Hopkins for three of the last six years. He is a well-respected lecturer and travels nationally to speak at conferences and educational workshops about novel therapies in lung and esophagus cancer. Make A Gift. Dr. Hales is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Thymic Epithelial Tumor, Non-Small Cell Lung Cancer (NSCLC), and Endoscopy.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC).

Josephine (Joy) Feliciano, M.D., is an assistant professor of oncology at The Johns Hopkins University School of Medicine and a faculty member of the Johns Hopkins Kimmel Cancer Center. She serves as medical director of the Thoracic Oncology Program at Johns Hopkins Bayview Medical Center, as well as co-director of the outpatient oncology clinic at Johns Hopkins Bayview. Dr. Feliciano completed both undergraduate and postgraduate medical training at Georgetown University, as well as residency training, where she was selected as chief resident. She spent three years at Northwestern completing clinical training in hematology and oncology, then joined the faculty at University of Maryland Greenberg Cancer Center. At the University of Maryland, Feliciano focused on lung cancer screening and health disparities research for patients with lung cancer. While there, she also earned a certificate degree in the Epidemiology and Human Genetics Program for Clinical Investigation. Dr. Feliciano is also a member of the Miller Coulson Academy of Clinical Excellence. She also serves as the inaugural Medical Director of the Sidney Kimmel Cancer Diagnostic and Treatment Planning Center. Dr. Feliciano is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Gastroesophageal Junction Cancer.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.

Md Siddiqui is a Hematologist Oncology specialist and a Hematologist in Salisbury, Maryland. Dr. Siddiqui is rated as an Experienced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Pulmonary Embolism, Inflammatory Breast Cancer, Angiosarcoma, and Childhood Iron Deficiency Anemia. Dr. Siddiqui is currently accepting new patients.

Katherine Scilla is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Scilla is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, and Tissue Biopsy. Dr. Scilla is currently accepting new patients.

Patrick Forde is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Forde is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Bone Marrow Transplant. Dr. Forde is currently accepting new patients.

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Suman Rao is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Rao is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC). Dr. Rao is currently accepting new patients.

Justinian Ngaiza is a Hematologist Oncology specialist and a Hematologist in Berlin, Maryland. Dr. Ngaiza is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Von Willebrand Disease (VWD), Lung Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Ngaiza is currently accepting new patients.

Kevin Chen is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Chen has been practicing medicine for over 18 years and is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), ALK-Positive Non-Small Cell Lung Cancer, Lung Adenocarcinoma, and Squamous Cell Lung Carcinoma.

Qamar Zaman is a Hematologist Oncology provider in Cumberland, Maryland. Dr. Zaman is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Anal Cancer, Thrombocytopenia, Non-Hodgkin Lymphoma, Gastric Lymphoma, and Bone Marrow Aspiration. Dr. Zaman is currently accepting new patients.

Charles Padgett is an Oncologist in Baltimore, Maryland. Dr. Padgett is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Lung Adenocarcinoma, Large-Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), and ALK-Positive Non-Small Cell Lung Cancer. Dr. Padgett is currently accepting new patients.

Richard Schraeder is a Hematologist Oncology specialist and a Hematologist in Towson, Maryland. Dr. Schraeder is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), and Retroperitoneal Liposarcoma. Dr. Schraeder is currently accepting new patients.

Gurdeep Chhabra is a Hematologist Oncology specialist and a Hematologist in California, Maryland. Dr. Chhabra is rated as a Distinguished provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Inflammatory Breast Cancer, Paget Disease of the Breast, Colorectal Cancer, and Small Cell Lung Cancer (SCLC). Dr. Chhabra is currently accepting new patients.

Dr. Lam treats patients with lung cancer, esophageal cancer, mesothelioma, and other thoracic cancers. He directs the Thoracic Oncology Clinical Research Program and the Esophageal Cancer Research Program at Johns Hopkins. Dr. Lam is a clinical and translational researcher with a focus on cancer genomics, liquid biopsies, and novel immunotherapies such as vaccines and cell therapies. He has been recognized with a Conquer Cancer Foundation/ASCO Career Development Award, an LCFA/IASLC/BMS Young Investigator Award, and as a Gilead Research Scholar. Dr. Lam is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Squamous Cell Lung Carcinoma, and Small Cell Lung Cancer (SCLC).

Dr. Kristen Marrone is a thoracic medical oncology specialist in Baltimore, caring for patients with lung cancer and esophageal cancer. She is the Program Director of the Hematology/Medical Oncology Fellowship Program at the Johns Hopkins School of Medicine. Dr. Marrone received her undergraduate degree in psychology with a neuroscience concentration from Pennsylvania State University. She earned her M.D. from Drexel University College of Medicine. She completed her residency at Yale-New Haven Hospital and performed a fellowship in medical oncology at Johns Hopkins University School of Medicine. Dr. Marrone joined the Johns Hopkins faculty in 2017. Her research interests include clinical trial development and translational studies focusing on optimization of immunotherapy in oncogene driven non-small cell lung cancer. Dr. Marrone is a member of the American Association of Cancer Research, the American Society of Clinical Oncology, the International Association for Study of Lung Cancer and the Society for Immunotherapy in Cancer. Dr. Marrone is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Squamous Cell Lung Carcinoma.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Wise is a pulmonary, critical care physician. He is an expert in the diagnosis and treatment of patients with obstructive lung disease, including those with asthma and COPD. He is a consultant for patients with scleroderma and interstitial lung disease. He has expertise in pulmonary physiology and lung function testing. Dr. Wise’s research focus is the conduct of multi-center clinical trials in airway diseases and related translational research. Dr. Wise is the co-director of the Pulmonary T32 Multi-disciplinary Training Program in Pulmonary Disease. Dr. Wise is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. His top areas of expertise are Systemic Sclerosis (SSc), Interstitial Lung Disease, Acute Interstitial Pneumonia, and Sarcoidosis.

Dr. K. Ranh Voong specializes in thoracic malignancies, including lung, esophageal, thymic cancers, and mesothelioma. She treats patients at both the Johns Hopkins Thoracic Center of Excellence at Johns Hopkins Bayview and at the Proton Center at Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, IMRT for tumors involving the chest. She is the Principal Investigator on grants from Lung Cancer Research Foundation and Hopkins-Wellspan. She is the Principal Investigator of a prospective study evaluating the immunogenic effects of SABR alone on systemic T cell response in patients with stage I NSCLC. She is the principal investigator of a multi-institutional prospective trial showing that routine review of patient-reported outcome measures informs radiation on-treatment toxicity burden assessment and care delivery. She was the Quality of Life Co-chair of a Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (NRG-LU006). She has been invited to participate in national and regularly lectures on thoracic malignancies and protons for thoracic malignancies therapy. In her research, Dr. Voong is dedicated to improving the outcomes of patients with thoracic malignancies, by exploring avenues to better understand and optimize the delivery of radiotherapy. Dr. Voong is also the Program Director for the Radiation Oncology Residency Program. She mentors residents, medical students. Make A Gift. Dr. Voong is rated as an Advanced provider by MediFind in the treatment of Large-Cell Lung Carcinoma. Her top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC).